{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:38:29Z","timestamp":1789907909222,"version":"4.0.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005620","name":"North Carolina GlaxoSmithKline Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaip.2018.08.036","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T16:48:01Z","timestamp":1536684481000},"page":"122-130.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis"],"prefix":"10.1016","volume":"7","author":[{"given":"Thomas B.","family":"Casale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Pacou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mesana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Farge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn X.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.08.036_bib1","author":"World Health Organization"},{"key":"10.1016\/j.jaip.2018.08.036_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2018.08.036_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2018.08.036_bib4","doi-asserted-by":"crossref","first-page":"e005748","DOI":"10.1136\/bmjopen-2014-005748","article-title":"Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study","volume":"5","author":"Talini","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2018.08.036_bib5","first-page":"1","article-title":"Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice","volume":"9","author":"Price","year":"2016","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2018.08.036_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.coi.2008.04.001","article-title":"IL-5 and eosinophilia","volume":"20","author":"Takatsu","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaip.2018.08.036_bib7","author":"Global Initiative for Asthma"},{"key":"10.1016\/j.jaip.2018.08.036_bib8","series-title":"Nucala [prescribing information]","year":"2017"},{"key":"10.1016\/j.jaip.2018.08.036_bib9","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.jaip.2018.08.036_bib10","series-title":"Cinqair [prescribing information]","year":"2016"},{"key":"10.1016\/j.jaip.2018.08.036_bib11","series-title":"Cinqaero [summary of product characteristics]","author":"European Medicines Agency (EMA)","year":"2017"},{"key":"10.1016\/j.jaip.2018.08.036_bib12","series-title":"Fasenra [prescribing information]","year":"2017"},{"key":"10.1016\/j.jaip.2018.08.036_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425255.2017.1359253","article-title":"Pharmacokinetic\/pharmacodynamics drug evaluation of benralizumab for the treatment of asthma","volume":"13","author":"Matera","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jaip.2018.08.036_bib14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib16","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2018.08.036_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2018.08.036_bib18","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.08.036_bib19","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"the SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2018.08.036_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jaip.2018.08.036_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jaip.2018.08.036_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cea.12853","article-title":"Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials","volume":"47","author":"Cabon","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.08.036_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2288-8-56","article-title":"Performing meta-analysis with incomplete statistical information in clinical trials","volume":"8","author":"Ma","year":"2008","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaip.2018.08.036_bib24","series-title":"NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"Dias","year":"2014"},{"key":"10.1016\/j.jaip.2018.08.036_bib25","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"10.1016\/j.jaip.2018.08.036_bib27","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib28","first-page":"A3699","article-title":"Benralizumab reduces exacerbations and improves lung function in adults with uncontrolled eosinophilic asthma","volume":"189","author":"Castro","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000444799","article-title":"the Asian Benralizumab Study Group. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan","volume":"169","author":"Park","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.08.036_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A\u00a0randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib31","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib32","series-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","year":"2009"},{"key":"10.1016\/j.jaip.2018.08.036_bib33","first-page":"A1234","article-title":"Exposure-response analysis for determination of benralizumab optimal dosing regimens in adults with asthma","volume":"189","author":"Wang","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2018.08.036_bib35","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.330.7499.1080","article-title":"Why clinicians are natural Bayesians","volume":"330","author":"Gill","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jaip.2018.08.036_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000445215","article-title":"A\u00a0player and coordinator: the versatile roles of eosinophils in the immune system","volume":"43","author":"Long","year":"2016","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.jaip.2018.08.036_bib37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1177\/0091270009337512","article-title":"Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials","volume":"49","author":"Wang","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jaip.2018.08.036_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/psp4.12160","article-title":"Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and patients with asthma","volume":"6","author":"Wang","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818305762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818305762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:16:49Z","timestamp":1761974209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818305762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2213219818305762"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.08.036","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.08.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}